Splice variants of activation induced deaminase (AID) do not affect the efficiency of class switch recombination in murine CH12F3 cells by Sala, Cesare et al.
RESEARCH ARTICLE
Splice Variants of Activation Induced
Deaminase (AID) Do Not Affect the
Efficiency of Class Switch Recombination in
Murine CH12F3 Cells
Cesare Sala1☯, Giorgio Mattiuz1☯, Silvia Pietrobono1,2☯, Andrea Chicca1¤, Silvestro
G. Conticello1,3*
1 Core Research Laboratory—Istituto Toscano Tumori, Firenze, Italy, 2 Department of Medical
Biotechnologies, University of Siena, Siena, Italy, 3 Department of Oncology—Azienda Ospedaliero-
Universitaria Careggi, Firenze, Italy
¤Current Address: Institute of Biochemistry and Molecular Medicine, University of Bern, Bern, Switzerland
☯ These authors contributed equally to this work.
* silvo.conticello@ittumori.it
Abstract
Activation Induced Deaminase (AID) triggers the antigen-driven antibody diversification pro-
cesses through its ability to edit DNA. AID dependent DNA damage is also the cause of ge-
netic alterations often found in mature B cell tumors. A number of splice variants of AID
have been identified, for which a role in the modulation of its activity has been hypothesized.
We have thus tested two of these splice variants, which we find catalytically inactive, for
their ability to modulate the activity of endogenous AID in CH12F3 cells, a murine lymphoma
cell line in which Class Switch Recombination (CSR) can be induced. In contrast to full-
length AID, neither these splice variants or a catalytically impaired AID mutant affect the effi-
ciency of Class Switch Recombination. Thus, while a role for these splice variants at the
RNA level remains possible, it is unlikely that they exert any regulatory effect on the function
of AID.
Introduction
Activation Induced Deaminase (AID) is the DNA editing enzyme that begins the antigen driv-
en diversification processes in activated B cells through its ability to deaminate DNA [1–3].
Whereas AID action is physiologically exerted on the immunoglobulin locus, AID dependent
damage can induce mutations and chromosomal translocations in a cohort of other loci. Evi-
dence for this comes from genetic analysis of tumors originating from mature B cells [4–6] as
well as from experimental systems [7–13]. A number of regulatory safeguards limits the effects
of AID in B cells in order to keep under control its potential damaging effects, from transcrip-
tion [14,15], to cellular localization [16–23] and posttranslational modifications [24–26].
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Expression of AID has been found in a number of B cell tumors [27–36]. Together with the
full-length form of AID, other splice transcripts have been identified in B cell tumors, initially,
and then in normal B cells [27–35,37,38] (Fig. 1A). Indeed, the presence of the various splice
variants has been inversely correlated to the mutational status of the immunoglobulins in B-
cell chronic lymphocytic leukemia [27,29–31,35]. This has opened the possibility that at least
some of these splice variants might be part of the regulatory network of AID.
While initially deemed as catalytically active [34], subsequent reports clarified that AID
splice variants are neither able to support deamination of DNA nor to trigger antibody diversi-
fication on their own [39,40]. Yet, even an inactive isoform could play a role in the regulation
of AID: interaction with the catalytically active AID itself or with other molecules in its path-
way could modify the physiologic activity of AID. In order to clarify this point we have thus
tested the ability of some of these splice isoforms to affect the efficiency of Class Switch Recom-
bination (CSR) in CH12F3 cells, a murine lymphoma cellular model in which the efficiency of
CSR can be assessed [41].
Materials and Methods
Plasmids
The coding sequences of AID splice isoforms were obtained by RT-PCR (primer forward,
AAAAAGCTTACCATGGACAGCCTCTTGATG; reverse, TTTCTCGAGTCAAAGTCC-
CAAAGTACGAAATG) from an RNA sample of B cell chronic lymphocytic leukemia (kindly
provided by Dr. F. Forconi) and cloned either into the AID encoding pTrc99A plasmid for bac-
terial expression ([2]; SnaBI and XhoI sites) or in the pAID-express-puro2 plasmid ([42]; prim-
er forward, AAAGCTAGCACCATGGACAGCCTCTTGATG and reverse,
AAAGCTAGCACCATGGACAGCCTCTTGATG; BglII and NheI sites), in which the ß-actin
promoter drives the expression of AID in mammalian cells alongside an EGFP reporter gene,
linked to the AID transcript through an internal ribosome entry site (IRES). The catalytically
inactive AID E58A mutant was prepared by site directed mutagenesis on the AID encoding
construct using the primers forward, CTGCCACGTGGCATTGCTCTTCCTCCGC and re-
verse, GGAAGAGCAATGCCACGTGGCAGCCGTT. The mutator activity of the splice vari-
ants was assayed in a bacterial assay in which the frequency of revertant colonies is measured
after rifampicin treatment [2].
Cells
HEK293T cells [43] were maintained in DMEM supplemented with 10% FBS, 2mM L-Gluta-
mine, and penicillin/streptomycin at 37°C in 5% CO2. Transient transfection was performed
using X-tremeGene HP DNA transfection reagent (Roche Diagnostics, Basel, Switzerland) ac-
cording to manufacturer’s instructions.
CH12F3 cells (kindly provided by Eva Severinson and Tasuku Honjo) [41] were maintained
in RPMI1640 supplemented with 10% FBS, 50 μM ß-mercaptoethanol, 2mM L-Glutamine,
1mM Sodium pyruvate and penicillin/streptomycin at 37°C in 5% CO2. The plasmids have
been transfected in CH12F3 cells by electroporation using a Gene Pulser II electroporator
(Biorad, Hercules, CA) (Voltage = 250V; Capacity = 500 μF; Resistance =1.) and independent
stable clones were selected through puromycin selection (0.6 μg/ml). Selected clones were then
screened for EGFP expression (coexpressed with AID via an IRES) by flow cytometry.
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Fig 1. Schematic representation of the splice variants of AID and their activity in bacteria. (A) The
exonic structure of the splice isoforms is shown. The position of functional features of the full-length AID
(AID-FL) is indicated: the catalytic domain, the cytoplasmic retention signal (CRS; [20]) and the nuclear
export signal (NES; [16–19]). The coding sequence appears in grey and the retained intron 3 is indicated
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Analysis of Class Switch Recombination
Class Switch Recombination in CH12F3 cells was induced with TGF-ß (2 ng/ml), IL4 (2 μg/ml)
and anti-CD40 antibody (0.5 mg/ml) as described in Nakamura et al. [41], in medium contain-
ing 30% FBS. After 72 hours in culture CSR was assayed in stimulated cells by FACS using an
anti-IgA antibody conjugated with RPE (Southern Biotech, Birmingham, AL; 1:100). Flow cy-
tometry analysis was performed on a Accuri C6 flow cytometer with a standard configuration
(BD Biosciences, San Jose, CA).
Analysis of the expression levels
The protein levels of AID variants from induced bacteria or transiently transfected HEK293T
cells were assayed by western blot analysis after lysis with RIPA buffer and SDS-PAGE. A
monoclonal antibody raised against AID N-terminus was used (clone 52–1; 1:1000; [44]). ß-
Actin was used as loading control (monoclonal Ab, clone AC-15, lot 117K4873, Sigma, St
Louis, MI, USA; 1:10000).
Quantitative real-time PCR (qPCR) was carried out to analyze the transcription level of en-
dogenous and exogenous AID in CH12F3 cells. Total RNA was isolated with TriPure Isolation
Reagent (Roche Diagnostics) and subjected to DNase I treatment (Roche Diagnostics). Reverse
transcription was performed with High Capacity cDNA Reverse Transcription Kit (Life Tech-
nologies, Paisley, UK). The qPCR reactions were performed at 60°C using SsoFastTM Eva-
Green Supermix (Bio-Rad, Hercules, CA, USA) on a Rotorgene-Q (Qiagen) and analyzed
using β-Actin as housekeeping gene. Primer sequences are: murine AID, CTCCTGCTCACTG-
GACTTCG (f), AGGCTGAGGTTAGGGTTCCA (r); human AID, CAGCCTCTTGAT-
GAACCGGA (f), CGTGGCAGCCGTTCTTATTG (r); murine β-Actin,
GGCTCCTAGCACCATGAAG (f), GAAAGGGTGTAAAACGCAGC (r).
Statistical analysis
All statistical analyses were performed using Prism (Graphpad, La Jolla, CA USA). The Kruskal
Wallis Test with post hoc Dunn's multiple comparison test was used for the rifampicin assay.
One-way ANOVA with Tukey’s multiple comparison test was performed to analyze the Class
Switch Recombination.
Results and Discussion
We cloned two of the splice isoforms of AID (AID-ivs3 and AID-ΔE4) that encode for truncat-
ed forms of AID in which either the fourth exon is skipped or the fourth intron is retained
(Fig. 1A). In either case such alternative splicing results in the lack of the C-terminal 57 amino
acids of the catalytically active AID. These isoforms lack both the Nuclear Export Signal, neces-
sary for an efficient CSR, and a cytoplasmic retention signal [16–20]. After cloning these splice
variants in bacterial expression vectors (Fig. 1B), we tested their ability to induce a mutator
(AID-ivs3) by the angle-striped pattern. The asterisks indicate the AID isoforms tested in the study. (B)
Western blot analysis showing the expression levels of AID-FL, AID-ΔE4, AID-ivs3, or an empty plasmid in
KL16 bacteria after induction with IPTG. Equal amounts of protein lysates (10 μg) were loaded on
SDS-PAGE. The apparent molecular weights from prestained protein ladder are shown on left. The arrows
indicate the expected molecular weight of the AID isoforms. The asterisk indicates an unspecific band. The
asterisk indicates an unspecific band. (C) Rifampicin assay using the various AID isoforms. Only the
revertants resistant to rifampicin can grow. While AID induces a mutator phenotype (P<10−3 by Dunn’s
multiple comparison test), the tested splice variants display levels of revertants similar to the negative control
(empty plasmid). The mutation rate is calculated after normalization with Ampicillin resistant viable colonies.
The median value is indicated.
doi:10.1371/journal.pone.0121719.g001
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phenotype in bacteria in the rifampicin-resistance reversion assay [2]. The inability of the
splice variants of AID to induce an increased level of revertants suggests that they are catalyti-
cally inactive, as suggested by the previous in vitro analyses [39,40] (Fig. 1C).
In order to assess the effects of these splice variants on Class Switch Recombination, we
cloned them in a mammalian expression vector and we tested them in HEK293T cells. Com-
pared to the full-length AID, the AID-ΔE4 variant consistently appeared expressed at lower
levels, whereas the AID-ivs3 variant, which differs in its C-terminus from AID-ΔE4, was ex-
pressed at slightly higher levels (Fig. 2). This result is compatible with the increased instability
of the splice variants observed by Rebhandl et al. [45].
We next transfected all the mammalian expression constructs in CH12F3 cells, and we have
selected clones expressing them by puromycin-selection and expression of the EGFP reporter.
Quantitative real-time PCR of transfected CH12F3 cells before and after induction with TGF-
ß, IL-4 and CD40 stimulation suggests that expression of the exogenous AID variants, at least
at the transcriptional level, matches that of endogenous AID in stimulated cells (Fig. 3). Due to
technical limitations, it is not possible to assess AID protein levels in CH12F3 cells, but it is rea-
sonable to assume that protein levels of AID splice variants should be proportional to those ob-
served in HEK293T cells and they might be preferentially degraded through the proteasome
[45]. On the other hand, it must be taken into account that—contrarily to full-length AID—the
splice variants are predominantly nuclear [39]. The probable stoichiometric ratio between
wild-type and splice variant would not support a direct interaction between the isoforms.
Nonetheless, even though steady-state levels of the splice variants could be lower than those of
Fig 2. Expression of the AID variants in HEK293T cells.Western blot analysis of HEK293T cells
transiently transfected with the various constructs (AID-FL, AID-ΔE4, AID-ivs3, AIDE58A). Equal amounts of
protein lysates (30 μg) were loaded on SDS-PAGE. ß-actin was used as a loading control. The apparent
molecular weights from prestained protein ladder are shown on left. The arrows indicate the expected
molecular weight of the AID isoforms. The asterisks indicate unspecific bands.
doi:10.1371/journal.pone.0121719.g002
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endogenous AID in stimulated CH12F3 cells, it could still be possible that the splice variants
could interfere with the physiological activity of AID through the catabolic pathway.
To test whether any of these constructs could modulate the activity of the induced endoge-
nous AID, we have induced CSR in the selected clones with TGF-ß, IL-4 and CD40 stimula-
tion. Cells were assayed 72 hours after stimulation, a timepoint that usually provides high
levels of CSR (~50%). Indeed, only overexpression of the full-length AID elicited a slight in-
crease (not statistically significant) in the efficiency of CSR. All other constructs showed levels
of CSR very similar to those of the controls (Fig. 4A, B). Similar results were obtained analyzing
the EGFP(+) population from transiently transfected CH12F3 cells (Fig. 4C). Thus, our data
suggest that overexpression of the catalytically inactive natural isoforms of AID is not able to
modulate the activity of the endogenous AID, at least with regards to the Class Switch
Recombination process.
Conclusions
A number of splice variants of AID have been identified in normal B cells and in lymphoproli-
ferative diseases beyond the full-length one [27–36], and their presence correlated to the prog-
nosis of the disease [27,29–31,35]. However, their functional significance is controversial
[34,39]. The absence of catalytic activity ([39], our data) suggests that—if translated—their ef-
fect might be indirect, through their interplay with the pathways involved in the antigen-driven
antibody diversification processes. Indeed, our results exclude that coexpression with endoge-
nous AID substantially alters the efficiency of CSR (as opposed to the overexpression of full-
length AID). Our results do not rule out the possibility that these alternatively spliced isoforms
of AID could still play a role, either as transcripts or simply because their transcription com-
petes with that of the full-length AID.
Fig 3. Expression of the AID variants in CH12F3 cells.Quantitative real-time PCR showing the expression
levels of endogenous (murine) and exogenous (human) AID from representative clones of CH12F3 cells
stably transfected with the constructs for AID-FL, AID-ΔE4, AID-ivs3, AIDE58A, or from control cells. Basal
expression levels (gray) are compared to those in stimulated cells (dark colums).
doi:10.1371/journal.pone.0121719.g003
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Fig 4. AID variants do not affect Class Switch Recombination in CH12F3 cells. (A) FACS profiles of
representative CH12F3 clones stably expressing AID-FL, AID-ivs3, AID-ΔE4 AIDE58A, or an EGFP negative
control. Cells were induced for CSR and assayed by FACS after 72 hr. The numbers in the upper-right
quadrants indicate the percentage of cells within the scatter window that are sIgA(+)/EGFP(+). (B) Each
datapoint in the plot represents the percentage of sIgA(+)/EGFP(+) cells in an independent clone expressing
the various constructs. While there is an increase in the efficiency of the CSR in the clones transfected with
full-length AID, none of the samples reaches statistical significance (one-way ANOVA coupled with Tukey’s
test). The median level of CSR is indicated. (C) CSR analysis of cells transiently transfected with the
constructs encoding for AID FL, AID-ΔE4 and AID-ivs3, AID-E58A, and a plasmid containing only the EGFP
negative control. The analysis was performed on the bulk of transfected cells after 48 hours of selection with
puromycin and 72 hours after induction with the stimulation cocktail. Transfected EGFP(+) cells represented
~2% of the total population. The only sample affecting the CSR is the one expressing the full-length AID (one-
way ANOVA coupled with Tukey’s test, P = 0.0004). The histograms represent the mean of four different
experiments and the standard error is shown.
doi:10.1371/journal.pone.0121719.g004
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Supporting Information
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